Information Journal Paper
APA:
Copy. (2017). Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open label, non-randomised, prospective, first-in-human phase 1 clinical trial. LANCET, 390(10101), 1511-1520. SID. https://sid.ir/paper/680686/en
Vancouver:
Copy. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open label, non-randomised, prospective, first-in-human phase 1 clinical trial. LANCET[Internet]. 2017;390(10101):1511-1520. Available from: https://sid.ir/paper/680686/en
IEEE:
Copy, “Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open label, non-randomised, prospective, first-in-human phase 1 clinical trial,” LANCET, vol. 390, no. 10101, pp. 1511–1520, 2017, [Online]. Available: https://sid.ir/paper/680686/en